ADJUVANT THERAPY IN MELANOMA: A REVIEW OF CONTEMPORARY TREATMENT STRATEGIES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5764Keywords:
Melanoma, Adjuvant Therapy, Targeted Therapy, Immune Checkpoint InhibitorsAbstract
Melanoma is a highly aggressive skin cancer with a steadily increasing annual incidence. Although it accounts for only 1% of diagnosed skin cancers, it has the highest mortality rate among them. Therefore, it is essential to continuously develop treatment methods and improve long-term outcomes. In recent years, a breakthrough has been the introduction of adjuvant therapy following surgical treatment, which has become the standard of treatment. This has led to an increase in recurrence-free survival and overall survival in high-risk patients. Immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies, as well as targeted therapy for patients with BRAF mutations, have become part of the standard of care. These are recommended for patients with stage IIB–IV melanoma at high risk of recurrence to eliminate micrometastases. Various treatment regimens targeting different patient subgroups are still being investigated to optimize outcomes and minimize adverse effects. This paper reviews and discusses current adjuvant treatment strategies for melanoma. In addition, it highlights the emerging role and future potential of these therapies in the neoadjuvant setting.
References
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., Baboud, J., Balasundaram, M., Balu, S., Barnabas, N., Bartlett, J., Bartlett, P., Bastian, B. C., Baylin, S. B., Behera, M., … Zou, L. (2015). Genomic classification of cutaneous melanoma. Cell, 161(7), 1681–1696. https://doi.org/10.1016/j.cell.2015.05.044
American Cancer Society. (2026). Cancer facts and figures 2026. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html
Blank, C. U., Lucas, M. W., Scolyer, R. A., Van De Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., Pulleman, S. M., Gonzalez, M., Torres Acosta, A., Van Houdt, W. J., Lo, S. N., Kuijpers, A. M. J., Spillane, A., Klop, W. M. C., Pennington, T. E., … Long, G. V. (2024). Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. The New England Journal of Medicine, 391(18), 1696–1708. https://doi.org/10.1056/NEJMoa2402604
Blumenröther, A.-K., Fang, Y., El Saadany, T., Ramelyte, E., Hasan Ali, O., Kündig, T., Mihic-Probst, D., Steiner, S., Maurer, A., Dummer, R., Mangana, J., & Maul, L. V. (2025). Neoadjuvant therapy in resectable advanced melanoma: Swiss real-world data. Cancers, 18(1), 98. https://doi.org/10.3390/cancers18010098
Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., … Mukhametshina, G. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): Health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 22(5), 655–664. https://doi.org/10.1016/S1470-2045(21)00081-4
Brenner, M., & Hearing, V. J. (2008). The protective role of melanin against UV damage in human skin. Photochemistry and Photobiology, 84(3), 539–549. https://doi.org/10.1111/j.1751-1097.2007.00226.x
Breslow, A. (1970). Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of Surgery, 172(5), 902–908. https://doi.org/10.1097/00000658-197011000-00017
Brown, V. L., Harwood, C. A., Crook, T., Cronin, J. G., Kelsell, D. P., & Proby, C. M. (2004). p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. Journal of Investigative Dermatology, 122(5), 1284–1292. https://doi.org/10.1111/j.0022-202X.2004.22501.x
Caraviello, C., Nazzaro, G., Tavoletti, G., Boggio, F., Denaro, N., Murgia, G., Passoni, E., Benzecry Mancin, V., & Marzano, A. V. (2025). Melanoma skin cancer: A comprehensive review of current knowledge. Cancers, 17(17), 2920. https://doi.org/10.3390/cancers17172920
Davis, L. E., Shalin, S. C., & Tackett, A. J. (2019). Current state of melanoma diagnosis and treatment. Cancer Biology & Therapy, 20(11), 1366–1379. https://doi.org/10.1080/15384047.2019.1640032
Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Gasal, E., Tan, M., … Schadendorf, D. (2020). Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. The New England Journal of Medicine, 383(12), 1139–1148. https://doi.org/10.1056/NEJMoa2005493
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., … Robert, C. (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. The New England Journal of Medicine, 378(19), 1789–1801. https://doi.org/10.1056/NEJMoa1802357
Eljilany, I., Castellano, E., & Tarhini, A. A. (2023). Adjuvant therapy for high-risk melanoma: An in-depth examination of the state of the field. Cancers, 15(16), 4125. https://doi.org/10.3390/cancers15164125
Front matter. (2020). In Abeloff’s clinical oncology (pp. i–iii). Elsevier. https://doi.org/10.1016/B978-0-323-47674-4.00124-9
Furue, M., Ito, T., Wada, N., Wada, M., Kadono, T., & Uchi, H. (2018). Melanoma and immune checkpoint inhibitors. Current Oncology Reports, 20(3), 29. https://doi.org/10.1007/s11912-018-0676-z
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., Brochez, L., Del Marmol, V., Dréno, B., Eggermont, A. M. M., Fargnoli, M. C., Forsea, A.-M., Höller, C., Kaufmann, R., Kelleners-Smeets, N., Lallas, A., Lebbé, C., … Mandala, M. (2025). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment—Update 2024. European Journal of Cancer, 215, 115153. https://doi.org/10.1016/j.ejca.2024.115153
Goldstein, A. M., Chan, M., Harland, M., Gillanders, E. M., Hayward, N. K., Avril, M.-F., Azizi, E., Bianchi-Scarra, G., Bishop, D. T., Bressac-de Paillerets, B., Bruno, W., Calista, D., Cannon Albright, L. A., Demenais, F., Elder, D. E., Ghiorzo, P., Gruis, N. A., Hansson, J., Hogg, D., … the Melanoma Genetics Consortium (GenoMEL). (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Research, 66(20), 9818–9828. https://doi.org/10.1158/0008-5472.CAN-06-0494
González-Gil, C., Ribera, J., Ribera, J. M., & Genescà, E. (2021). The yin and yang-like clinical implications of the CDKN2A/ARF/CDKN2B gene cluster in acute lymphoblastic leukemia. Genes, 12(1), 79. https://doi.org/10.3390/genes12010079
Green, K. J., Pokorny, J., & Jarrell, B. (2024). Dangerous liaisons: Loss of keratinocyte control over melanocytes in melanomagenesis. BioEssays, 46(11), 2400135. https://doi.org/10.1002/bies.202400135
Hauschild, A., Gogas, H., Tarhini, A., Middleton, M. R., Testori, A., Dréno, B., & Kirkwood, J. M. (2008). Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer, 112(5), 982–994. https://doi.org/10.1002/cncr.23251
Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., Van Den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., … Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723. https://doi.org/10.1056/NEJMoa1003466
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000). High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190. Journal of Clinical Oncology, 18(12), 2444–2458. https://doi.org/10.1200/JCO.2000.18.12.2444
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001). High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: Results of Intergroup Trial E1694/S9512/C509801. Journal of Clinical Oncology, 19(9), 2370–2380. https://doi.org/10.1200/JCO.2001.19.9.2370
Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., & Chapman, P. B. (2001). High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. Journal of Clinical Oncology, 19(5), 1430–1436. https://doi.org/10.1200/JCO.2001.19.5.1430
Kirkwood, J. M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M. S., & Rao, U. (2004). A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clinical Cancer Research, 10(5), 1670–1677. https://doi.org/10.1158/1078-0432.CCR-1103-3
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology, 14(1), 7–17. https://doi.org/10.1200/JCO.1996.14.1.7
Kobeissi, I., & Tarhini, A. A. (2022). Systemic adjuvant therapy for high-risk cutaneous melanoma. Therapeutic Advances in Medical Oncology, 14, 17588359221134087. https://doi.org/10.1177/17588359221134087
Kreuger, I. Z. M., Slieker, R. C., Van Groningen, T., & Van Doorn, R. (2023). Therapeutic strategies for targeting CDKN2A loss in melanoma. Journal of Investigative Dermatology, 143(1), 18–25.e1. https://doi.org/10.1016/j.jid.2022.07.016
Lee, C., Collichio, F., Ollila, D., & Moschos, S. (2013). Historical review of melanoma treatment and outcomes. Clinics in Dermatology, 31(2), 141–147. https://doi.org/10.1016/j.clindermatol.2012.08.015
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., … Kirkwood, J. M. (2017). Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. The New England Journal of Medicine, 377(19), 1813–1823. https://doi.org/10.1056/NEJMoa1708539
Luke, J. J., Ascierto, P. A., Khattak, M. A., De La Cruz Merino, L., Del Vecchio, M., Rutkowski, P., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Kirkwood, J. M. M., Robert, C., Grob, J.-J., De Galitiis, F., Schadendorf, D., Carlino, M. S., Wu, L., Fukunaga-Kalabis, M., Krepler, C., Eggermont, A. M., & Long, G. V. (2023). Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. Journal of Clinical Oncology, 41(17_suppl), LBA9505–LBA9505. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA9505
Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G. R., Simmons, B., Ye, C., Yan, Y., Schadendorf, D., Cinat, G., Fein, L. E., Brown, M., Guminski, A., … Whitman, E. (2018). Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Oncology, 19(4), 510–520. https://doi.org/10.1016/S1470-2045(18)30106-2
Mocellin, S., Pasquali, S., Rossi, C. R., & Nitti, D. (2010). Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute, 102(7), 493–501. https://doi.org/10.1093/jnci/djq009
Natarelli, N., Aleman, S. J., Mark, I. M., Tran, J. T., Kwak, S., Botto, E., Aflatooni, S., Diaz, M. J., & Lipner, S. R. (2024). A review of current and pipeline drugs for treatment of melanoma. Pharmaceuticals, 17(2), 214. https://doi.org/10.3390/ph17020214
Neagu, M., Constantin, C., & Zurac, S. (2025). Cutaneous melanoma in the context of aging. Medicina, 61(12), 2115. https://doi.org/10.3390/medicina61122115
Olivier, T., & Prasad, V. (2024). Neoadjuvant followed by adjuvant pembrolizumab in melanoma: Time biases in the data analysis of the SWOG S1801 trial. Translational Oncology, 45, 101959. https://doi.org/10.1016/j.tranon.2024.101959
Olsen, C. M., Pandeya, N., Thompson, B. S., Dusingize, J. C., Green, A. C., Neale, R. E., & Whiteman, D. C. (2019). Association between phenotypic characteristics and melanoma in a large prospective cohort study. Journal of Investigative Dermatology, 139(3), 665–672. https://doi.org/10.1016/j.jid.2018.09.022
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., Eisenstein, J. L., Chandra, S., Sosman, J. A., Kendra, K. L., Wu, R. C., Devoe, C. E., Deutsch, G. B., Hegde, A., Khalil, M., … Ribas, A. (2023). Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. The New England Journal of Medicine, 388(9), 813–823. https://doi.org/10.1056/NEJMoa2211437
Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012). A brief history of melanoma: From mummies to mutations. Melanoma Research, 22(2), 114–122. https://doi.org/10.1097/CMR.0b013e328351fa4d
Reijers, I. L. M., Menzies, A. M., Lopez-Yurda, M., Versluis, J. M., Rozeman, E. A., Saw, R. P. M., Van Houdt, W. J., Kapiteijn, E., Van Der Veldt, A. A. M., Suijkerbuijk, K. P. M., Eriksson, H., Hospers, G. A. P., Klop, W. M. C., Torres Acosta, A., Grijpink-Ongering, L., Gonzalez, M., Van Der Wal, A., Al-Mamgani, A., Spillane, A. J., … Blank, C. U. (2025). Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. European Journal of Cancer, 214, 115141. https://doi.org/10.1016/j.ejca.2024.115141
Reijers, I. L. M., Menzies, A. M., Van Akkooi, A. C. J., Versluis, J. M., Van Den Heuvel, N. M. J., Saw, R. P. M., Pennington, T. E., Kapiteijn, E., Van Der Veldt, A. A. M., Suijkerbuijk, K. P. M., Hospers, G. A. P., Rozeman, E. A., Klop, W. M. C., Van Houdt, W. J., Sikorska, K., Van Der Hage, J. A., Grünhagen, D. J., Wouters, M. W., Witkamp, A. J., … Blank, C. U. (2022). Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial. Nature Medicine, 28(6), 1178–1188. https://doi.org/10.1038/s41591-022-01851-x
Scolyer, R. A., Long, G. V., & Thompson, J. F. (2011). Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology, 5(2), 124–136. https://doi.org/10.1016/j.molonc.2011.03.002
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014). Pathways and therapeutic targets in melanoma. Oncotarget, 5(7), 1701–1752. https://doi.org/10.18632/oncotarget.1892
Sun, J., Carr, M. J., & Khushalani, N. I. (2020). Principles of targeted therapy for melanoma. Surgical Clinics of North America, 100(1), 175–188. https://doi.org/10.1016/j.suc.2019.09.013
Tarhini, A. A., & Kirkwood, J. M. (2009). Clinical and immunologic basis of interferon therapy in melanoma. Annals of the New York Academy of Sciences, 1182(1), 47–57. https://doi.org/10.1111/j.1749-6632.2009.05073.x
Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., Koon, H. B., Lawrence, D. P., Kendra, K. L., Minor, D. R., Lee, C. B., Albertini, M. R., Flaherty, L. E., Petrella, T. M., Streicher, H., … Kirkwood, J. M. (2020). Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. Journal of Clinical Oncology, 38(6), 567–575. https://doi.org/10.1200/JCO.19.01381
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbe, C., Whitaker, D., Puig, S., Van De Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025). Cutaneous melanoma. Nature Reviews Disease Primers, 11(1), 23. https://doi.org/10.1038/s41572-025-00603-8
Testori, A. A. E., Chiellino, S., & Van Akkooi, A. C. J. (2020). Adjuvant therapy for melanoma: Past, current, and future developments. Cancers, 12(7), 1994. https://doi.org/10.3390/cancers12071994
Cancer Research UK. (2025, January 2). TNM staging for melanoma skin cancer. https://www.cancerresearchuk.org/about-cancer/melanoma/stages-types/tnm-staging
Torres, S. M., Hughes, C. R., & Berwick, M. (2017). Melanoma and skin aging. In M. A. Farage, K. W. Miller, & H. I. Maibach (Eds.), Textbook of aging skin (pp. 903–912). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-47398-6_57
Versluis, J. M., Menzies, A. M., Sikorska, K., Rozeman, E. A., Saw, R. P. M., Van Houdt, W. J., Eriksson, H., Klop, W. M. C., Ch’ng, S., Van Thienen, J. V., Mallo, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Van Der Wal, A., Bruining, A., Van De Wiel, B. A., Scolyer, R. A., Haanen, J. B. A. G., … Blank, C. U. (2023). Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Annals of Oncology, 34(4), 420–430. https://doi.org/10.1016/j.annonc.2023.01.004
Weber, J. S., Del Vecchio, M., Mandala, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J. J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Maio, M., Middleton, M. R., Tang, T., Saci, A., De Pril, V., Lobo, M., Larkin, J. M. G., & Ascierto, P. A. (2019). Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Annals of Oncology, 30, v533–v534. https://doi.org/10.1093/annonc/mdz255
Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., Ascierto, P. A., Sandhu, S., Eigentler, T., Gutzmer, R., Hassel, J. C., Robert, C., Carlino, M. S., Di Giacomo, A. M., Butler, M. O., … Long, G. V. (2023). Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). Journal of Clinical Oncology, 41(3), 517–527. https://doi.org/10.1200/JCO.22.00533
Young, A. R., Potten, C. S., Nikaido, O., Parsons, P. G., Boenders, J., Ramsden, J. M., & Chadwick, C. A. (1998). Human melanocytes and keratinocytes exposed to UVB or UVA in vivo show comparable levels of thymine dimers. Journal of Investigative Dermatology, 111(6), 936–940. https://doi.org/10.1046/j.1523-1747.1998.00435.x
Zimmer, L., Livingstone, E., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F., Mohr, P., Hauschild, A., Schilling, B., Menzer, C., Kieker, F., Dippel, E., Rösch, A., Simon, J.-C., Conrad, B., Körner, S., … Utikal, J. (2020). Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 395(10236), 1558–1568. https://doi.org/10.1016/S0140-6736(20)30417-7
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Gabriela Płodzień, Nikola Król, Aleksandra Łoś, Karolina Majowicz-Czaszyńska, Inga Jakubczyk, Kacper Szkodziński, Jagoda Maternia, Wiktoria Pempuś, Aleksandra Blok, Dominik Wiater, Barbara Tomaszek
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
